Figure 4.

Anti-CS1 TRNT, in a stage of low tumor burden, significantly impacts the survival of 5T33MM mice. (a) Treatment schedule of 5T33MM mice with [²²⁵Ac]-sdAb1. Mice (n = 13/group) were treated with either saline buffer, [²²⁵Ac]-R3B23 sdAb (control sdAb) or [²²⁵Ac]-sdAb1 at day 4, 7, 10 and 13. At end-stage of disease, mice were sacrificed. (b) Body weight after α-TRNT with [²²⁵Ac]-sdAb1 in the 5T33MM model. (c) Survival curves after α-TRNT with [²²⁵Ac]-sdAb1 in the 5T33MM model. p values were determined using the log-rank test and found to be highly significant, ****p < .0001